10-K · June 5, 2026
TAO Synergies Inc. demonstrated significant growth in its transition to a cryptocurrency-focused business model, reporting revenue from TAO staking of $299,061 in 2025 and net losses of $29,075,807. The company has made…
Earnings analysis · 10-Q
TAOX earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The extracted 10-Q text does not include the statements of operations, balance sheets, cash flows, or MD&A metrics, so revenue, margins, EPS, liquidity, and free cash flow cannot be assessed. The principal disclosed…
Read full summary
The extracted 10-Q text does not include the statements of operations, balance sheets, cash flows, or MD&A metrics, so revenue, margins, EPS, liquidity, and free cash flow cannot be assessed. The principal disclosed development is that controls remained ineffective as of June 30, 2026, with weaknesses spanning segregation of duties, financial reporting, and IT controls. Management reported no material changes to the 2025 Form 10-K risk factors and provided no quantitative guidance.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Control weaknesses remain material
Management concluded that disclosure controls and procedures were ineffective as of June 30, 2026, citing weaknesses in payroll and banking segregation of duties, period-end reporting, and IT general controls.
-
Management affirms financial statement presentation
The company stated that its financial statements and other information for the periods presented fairly present its financial condition, results of operations, and cash flows in all material respects, notwithstanding the control weaknesses identified as of June 30, 2026.
-
Equity issued for investor relations
The company issued 22,563 common shares to IRTH Communications on January 16, 2026, and 1,025 and 1,181 shares to Neil Cataldi on March 6 and June 8, 2026, respectively, in exchange for investor-relations services.
-
No insider trading-plan changes
No directors or executive officers adopted, modified, or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during the quarter ended June 30, 2026.
What to watch
-
Ineffective disclosure controls
Disclosure controls were ineffective as of June 30, 2026, due to inadequate segregation of duties, ineffective period-end financial reporting processes, and ineffective IT general controls. Management also said these weaknesses may affect its ability to determine whether errors or inappropriate actions occurred.
-
Unresolved internal-control weakness
Management previously concluded that internal controls were not effective during the fiscal year ended December 31, 2025, because they failed to detect inappropriate application of U.S. GAAP; the issue remains unresolved as of June 30, 2026.
-
No new risk-factor update
The filing reports no material changes from the risk factors disclosed in the Form 10-K for the fiscal year ended December 31, 2025. Accordingly, the existing cryptocurrency, operating-cost, and regulatory risks identified in that 10-K remain applicable, with no new quantified risk-factor update in this 10-Q.
Management's outlook
No quantitative revenue or EPS outlook was provided in the extracted 10-Q text; the filing does not provide guidance fields.
Earlier filings 4
10-Q · May 13, 2026
TAO Synergies reported significant revenue growth from its pivot to cryptocurrency, with operating revenue reaching $388,774 in Q1 2026, a stark contrast to zero revenue in Q1 2025. The company registered a net income…
10-K · March 31, 2026
TAO Synergies (formerly Synaptogenix) completed a rapid strategic pivot in 2025 from a pure-play biopharmaceutical developer of Bryostatin-1 to a cryptocurrency treasury operator focused on accumulating and staking the…
10-Q · November 14, 2025
TAO Synergies reported its first staking revenue of $203,371 for Q3 2025 and a narrower GAAP loss (net loss attributable to common stockholders) of $3,968,457 (basic loss per share $1.56) versus a larger loss in Q3…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.